Pfizer PFE Q1 2021 Results
A woman holds a small bottle labeled with a “Coronavirus COVID-19 Vaccine” sticker and a medical syringe in front of the Pfizer logo displayed in this illustration taken on October 30, 2020.
In view of Ruvic | Reuters
Pfizer said on Tuesday that he planned to file a full U.S. application for approval of its Covid-19 vaccine with German drugmaker BioNTech at the end of this month. If the FDA approves, the company will be able to market the shot directly to consumers.
Releasing its first quarter financial results, the company also reported $ 3.5 billion in first quarter sales of its Covid-19 and reported profits and revenues that exceeded Wall Street expectations.
Here’s how Pfizer did compared to what Wall Street expected, according to average estimates compiled by Refinitiv:
- Adjusted EPS: 93 cents per share vs. 77 cents expected
- Turnover: $ 14.58 billion against $ 13.51 billion expected
The company now expects annual sales of the vaccine of $ 26 billion, up from its previous forecast of around $ 15 billion.
Pfizer shares rose 1.4% after the news.
This is a developing story. Please come back for updates.